
Phase 3 data demonstrate superiority of ponatinib, blinatumomab over imatinib, chemotherapy for patients with Ph–positive ALL
The study enrolled 236 patients with Ph–positive ALL and randomized 158 to ponatinib plus blinatumomab and 78 to imatinib plus chemotherapy as frontline therapy. The cohort had a median age of 55 years range, 24-82. Patients in the control group who had persistent disease or measurable residual disease reappearance were allowed to crossover to ponatinib plus blinatumomab.





